Work

AFT-16: Phase II trial of neoadjuvant and adjuvant atezolizumab and chemoradiation (CRT) for stage III non-small cell lung cancer (NSCLC).

Year: 2021

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2021.39.15_suppl.8513

Authors: Helen J. Ross, David E. Kozono, James John Urbanic, Terence Marques Williams, Carter DuFrane, Ilze Bara, Katja Schulze, Jane Michelle Brockman, Xiaofei F. Wang, Junheng Gao, Everett E. Vokes, Tom Stinchcombe

Institutions: Dana-Farber Cancer Institute, University of California San Diego, City Of Hope National Medical Center, Alliance Foundation Trials, Genentech, Duke University, Duke Cancer Institute, Duke University Health System, University of Chicago

Language: English

Topic: Lung Cancer Diagnosis and Treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Alliance for Clinical Trials in Oncology Foundation

OpenAlex ID: W3172638287

Cites:

Cited by: 37

Related to: 10